📰 First Negotiation News

First Negotiation News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from First Negotiation. Real-time updates on events, politics, business and more.

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular ...

June 20, 2023

Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease

United Kingdom United States Patrickj Mcenany David Schull Russo Drug Administration European Medicines Agency

Source: eagletribune.com

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

June 20, 2023

Vamorolone is Currently Under Review with the FDA for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation for Vamorolone... | June 20, 2023

United States United Kingdom Patrickj Mcenany European Medicines Agency Santhera Pharmaceuticals Health Canada

Source: marketscreener.com

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals

October 6, 2022

/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated...

United States Kaelan Hollon Thierry Chauche Ashleigh Palmer Jason Hoitt Olivier Bogillot

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

First Negotiation News Today

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular ...

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals

Explore More Categories